PCDHGA8

Across TCGA pan-cancer cohorts, PCDHGA8 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PCDHGA8 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PCDHGA8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHGA8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

THYM, SCLC, and PAAD are the cancer types where PCDHGA8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SCLC	DFS	Median	III,IV	0.082	0.548	.003	30	view →
PAAD	OS	Median	All	0.011	0.641	<.001	24	view →
PRAD	OS	Median	All	0.826	0.990	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.896	0.430	.015	12	view →
STAD	DFS	Median	III,IV	0.865	0.330	.034	3	view →
BLCA	DFS	Median	IV	0.122	0.475	.025	3	view →
SKCM	OS	Median	IV	0.133	0.621	.019	3	view →
LUSC	DFS	Median	II,III,IV	0.187	0.379	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PCDHGA8–THYM (OS)

Open the THYM breakdown →